Development and testing of AIDS vaccines

doi:10.1126/science.3293212

Account Information

Guest Alerts | Access Rights | My Account | Sign In

Site Navigation

Article Views

Article Tools

My Science

Science 22 July 1988:
Vol. 241. no. 4864, pp. 426 - 432
DOI: 10.1126/science.3293212

Prev | Table of Contents | Next

Articles

Science, Vol 241, Issue 4864, 426-432
Copyright © 1988 by American Association for the Advancement of Science

articles

Development and testing of AIDS vaccines

WC Koff and DF Hoth

Vaccine Research and Development Branch, AIDS Program, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Recent advances in delineating the molecular biology of human immunodeficiency virus type 1 (HIV-1) have led to innovative approaches to development of a vaccine for acquired immunodeficiency syndrome (AIDS). However, the lack of understanding of mechanisms of protective immunity against HIV-1, the magnitude of genetic variation of the virus, and the lack of effective animal models for HIV-1 infection and AIDS have impeded progress. The testing of AIDS vaccines also presents challenges. These include liability concerns over vaccine-related injuries; identification of suitable populations for phase 3 efficacy studies; balancing the ethical obligation to counsel research subjects to avoid high-risk behavior with the necessity to obtain vaccine efficacy data; and the effect of vaccine-induced seroconversion on the recruiting and welfare of trial volunteers. Several candidate AIDS vaccines are nevertheless currently under development, and some are undergoing phase 1 clinical trials. Rapid progress will depend on continued scientific advancement in conjunction with maximum use of resources, open information and reagent exchange, and a spirit of international collaboration.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:

The next steps toward a global AIDS vaccine.: W. Koff (1994)
Science 266, 1335-1337
| PDF »

HIV Vaccines: A Magic Bullet in the Fight Against AIDS?.: S. D. Pinkerton and P. R. Abramson (1993)
Eval Rev 17, 579-602
| Abstract » | PDF »

Scientific and social issues of human immunodeficiency virus vaccine development.: B. Haynes (1993)
Science 260, 1279-1286
| Abstract » | PDF »

Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.: C. Wang, D. Looney, M. Li, A. Walfield, J Ye, B Hosein, J. Tam, and F Wong-Staal (1991)
Science 254, 285-288
| Abstract » | PDF »

Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.: L Shen, Z. Chen, M. Miller, V Stallard, G. Mazzara, D. Panicali, and N. Letvin (1991)
Science 252, 440-443
| Abstract » | PDF »

Biological Agents in Infectious Diseases.: S. G. Louie and G. S. Jaresko (1991)
Journal of Pharmacy Practice 4, 326-341
| Abstract » | PDF »

The Ethical Conduct of Clinical Trials of HIV Vaccines.: W. K. Mariner (1990)
Eval Rev 14, 538-564
| Abstract » | PDF »

Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.: R. Orentas, J. Hildreth, E Obah, M Polydefkis, G. Smith, M. Clements, and R. Siliciano (1990)
Science 248, 1234-1237
| Abstract » | PDF »

The Emergence of Adolescents as a Risk Group for Human Immunodeficiency Virus Infection.: R. J. DiClemente (1990)
Journal of Adolescent Research 5, 7-17
| Abstract »

Progress in vaccines against AIDS.: D. Bolognesi (1989)
Science 246, 1233-1234
| PDF »

An Evaluation of an Undergraduate Course On Aids.: P. R. Abramson, J. C. Sekler, R. Berk, and M. Y. Cloud (1989)
Eval Rev 13, 516-532
| Abstract » | PDF »

Appropriate Collaboration between Industry and Government in the Development of an AIDS Vaccine.: N. A. Christakis and M. J. Panner (1989)
J. Law Med. Ethics 17, 130-138
| PDF »